US Bancorp DE Acquires 14,698 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

US Bancorp DE lifted its holdings in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 310.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 19,433 shares of the medical instruments supplier’s stock after acquiring an additional 14,698 shares during the quarter. US Bancorp DE’s holdings in OraSure Technologies were worth $70,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of OSUR. Geode Capital Management LLC lifted its position in shares of OraSure Technologies by 1.9% during the third quarter. Geode Capital Management LLC now owns 1,797,814 shares of the medical instruments supplier’s stock worth $7,678,000 after acquiring an additional 32,929 shares in the last quarter. Systematic Financial Management LP raised its stake in shares of OraSure Technologies by 14.9% during the 3rd quarter. Systematic Financial Management LP now owns 1,252,112 shares of the medical instruments supplier’s stock valued at $5,347,000 after purchasing an additional 162,364 shares during the period. BNP Paribas Financial Markets raised its stake in shares of OraSure Technologies by 27.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 855,951 shares of the medical instruments supplier’s stock valued at $3,655,000 after purchasing an additional 183,191 shares during the period. JPMorgan Chase & Co. lifted its holdings in OraSure Technologies by 5.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 847,933 shares of the medical instruments supplier’s stock worth $3,621,000 after purchasing an additional 46,216 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its stake in OraSure Technologies by 66.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 524,950 shares of the medical instruments supplier’s stock worth $2,242,000 after purchasing an additional 209,580 shares during the period. 93.50% of the stock is owned by institutional investors.

Insider Buying and Selling at OraSure Technologies

In related news, CEO Manner Carrie Eglinton bought 78,625 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were acquired at an average cost of $3.15 per share, with a total value of $247,668.75. Following the completion of the purchase, the chief executive officer now directly owns 1,259,664 shares of the company’s stock, valued at $3,967,941.60. This trade represents a 6.66 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director John P. Kenny purchased 47,659 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was bought at an average cost of $3.17 per share, for a total transaction of $151,079.03. Following the acquisition, the director now directly owns 70,915 shares in the company, valued at approximately $224,800.55. The trade was a 204.93 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 190,284 shares of company stock valued at $600,348 in the last 90 days. Corporate insiders own 3.40% of the company’s stock.

OraSure Technologies Price Performance

OSUR opened at $3.57 on Tuesday. OraSure Technologies, Inc. has a one year low of $2.69 and a one year high of $6.96. The firm has a market capitalization of $267.04 million, a P/E ratio of 23.80 and a beta of -0.02. The company has a fifty day moving average price of $3.73 and a 200-day moving average price of $3.93.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, March 4th.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.